image
Healthcare - Biotechnology - NASDAQ - US
$ 49.18
-3.09 %
$ 7.71 B
Market Cap
58.2
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TECH stock under the worst case scenario is HIDDEN Compared to the current market price of 49.2 USD, Bio-Techne Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TECH stock under the base case scenario is HIDDEN Compared to the current market price of 49.2 USD, Bio-Techne Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TECH stock under the best case scenario is HIDDEN Compared to the current market price of 49.2 USD, Bio-Techne Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TECH

image
$80.0$80.0$75.0$75.0$70.0$70.0$65.0$65.0$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
1.16 B REVENUE
1.97%
207 M OPERATING INCOME
-30.86%
168 M NET INCOME
-41.12%
299 M OPERATING CASH FLOW
17.53%
-203 M INVESTING CASH FLOW
23.57%
-122 M FINANCING CASH FLOW
-541.20%
316 M REVENUE
6.45%
38.7 M OPERATING INCOME
-18.37%
22.6 M NET INCOME
-35.26%
41.1 M OPERATING CASH FLOW
-51.25%
-8.87 M INVESTING CASH FLOW
-76.33%
-68 M FINANCING CASH FLOW
18.84%
Balance Sheet Bio-Techne Corporation
image
Current Assets 617 M
Cash & Short-Term Investments 153 M
Receivables 241 M
Other Current Assets 223 M
Non-Current Assets 2.09 B
Long-Term Investments 252 M
PP&E 342 M
Other Non-Current Assets 1.49 B
5.65 %8.93 %8.25 %9.33 %12.66 %55.18 %Total Assets$2.7b
Current Liabilities 159 M
Accounts Payable 38 M
Short-Term Debt 25.8 M
Other Current Liabilities 95.6 M
Non-Current Liabilities 476 M
Long-Term Debt 407 M
Other Non-Current Liabilities 69 M
5.98 %4.07 %15.05 %64.03 %10.87 %Total Liabilities$635.0m
EFFICIENCY
Earnings Waterfall Bio-Techne Corporation
image
Revenue 1.16 B
Cost Of Revenue 389 M
Gross Profit 770 M
Operating Expenses 563 M
Operating Income 207 M
Other Expenses 38.6 M
Net Income 168 M
1b1b1b1b800m800m600m600m400m400m200m200m001b(389m)770m(563m)207m(39m)168mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
66.41% GROSS MARGIN
66.41%
17.83% OPERATING MARGIN
17.83%
14.50% NET MARGIN
14.50%
8.13% ROE
8.13%
6.22% ROA
6.22%
7.28% ROIC
7.28%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bio-Techne Corporation
image
350m350m300m300m250m250m200m200m150m150m100m100m50m50m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 168 M
Depreciation & Amortization 112 M
Capital Expenditures -62.9 M
Stock-Based Compensation 38 M
Change in Working Capital -10.1 M
Others 29.5 M
Free Cash Flow 236 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bio-Techne Corporation
image
Wall Street analysts predict an average 1-year price target for TECH of $80.5 , with forecasts ranging from a low of $75 to a high of $84 .
TECH Lowest Price Target Wall Street Target
75 USD 52.50%
TECH Average Price Target Wall Street Target
80.5 USD 63.68%
TECH Highest Price Target Wall Street Target
84 USD 70.80%
Price
Max Price Target
Min Price Target
Average Price Target
858580807575707065656060555550504545Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
0.14% DIVIDEND YIELD
0.08 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.350.350.300.300.250.250.200.200.150.150.100.100.050.050.000.000.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.320.080.320.080.320.080.320.080.320.080.320.080.320.080.320.080.320.080.320.162015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 16
6. Ownership
Insider Ownership Bio-Techne Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.16 M USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
1.15 M USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Is Bio-Techne Stock the Right Pick for Your Portfolio Now? Bio-Techne's TECH GMP reagents, including GMP proteins and small molecules, remain a cornerstone of its cell therapy offering. Acquisitions have continued to play an important role in the company's efforts to expand its portfolio, as well as enter adjacent markets. zacks.com - 2 weeks ago
Bio-Techne to Present at Investor Conferences MINNEAPOLIS , May 29, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: William Blair 45th Annual Growth Stock Conference June 3, 2025 2:40 PM CDT Jefferies Global Healthcare Conference June 4, 2025 3:45 PM EDT Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. prnewswire.com - 2 weeks ago
CMB.TECH NV AND GOLDEN OCEAN GROUP LIMITED ANNOUNCE AGREEMENT AND PLAN OF MERGER Antwerp, May 28, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV AND GOLDEN OCEAN GROUP LIMITED ANNOUNCE AGREEMENT AND PLAN OF MERGER CMB.TECH NV (NYSE: CMBT & Euronext Brussels: CMBT) (“CMB.TECH”) and Golden Ocean Group Limited (NASDAQ: GOGL & Euronext Oslo Børs: GOGL) (“Golden Ocean”) are pleased to announce that they have signed an agreement and plan of merger (the “Merger Agreement”) for a stock-for-stock merger, as contemplated by the term sheet previously announced on 22 April 2025. The transaction is structured as a merger, with Golden Ocean merging with and into CMB.TECH Bermuda Ltd. globenewswire.com - 2 weeks ago
CMB.TECH results general meetings Antwerp, May 22, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”)  announces that today the General Meeting of Shareholders has approved the annual accounts for the year ended 31 December 2024. All other resolutions proposed by CMB.TECH's Supervisory Board have also been approved. globenewswire.com - 3 weeks ago
CMB.TECH announces Q1 2025 results CMB.TECH ANNOUNCES Q1 2025 RESULTS 1 BILLION USD CONTRACT BACKLOG ADDED ANTWERP, Belgium, 21 May 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT & Euronext: CMBT) reported its non-audited financial results today for the first quarter ended 31 March 2025. HIGHLIGHTS Financial highlights: Profit of USD 40.4 million in Q1 2025 CMB.TECH increases its contract backlog by USD 921 million (to USD 2.94 billion) Corporate highlights: CMB.TECH buys Hemen stake in Golden Ocean Term sheet signed for a stock-for-stock merger transaction between CMB.TECH and Golden Ocean Fleet highlights: Fortescue and CMB.TECH sign agreement for ammonia-powered Newcastlemax CMB.TECH and MOL sign landmark agreement for nine ammonia-powered vessels Delivery of 5 newbuilding vessels: Mineral Portugal, Mineral Osterreich, Mineral Suomi, Mineral Sverige and CTV Hydrocat 60 Previously announced sales generated a capital gain of USD 46.25 million: Suezmax Cap Lara (2007, 158,826 dwt), VLCC Alsace (2012 – 299,999 DWT) and Windcat 6 Sale of three VLCCs in Q1 2025, Iris (2012, 314,000 dwt), Hakata (2010, 302,550 dwt) & Hakone (2010, 302,624 dwt) as part of the fleet rejuvenation strategy. globenewswire.com - 3 weeks ago
ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA) ST. PAUL, Minn. , May 14, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady announced today three G-Rex Grants that have been awarded to faculty members at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA). prnewswire.com - 1 month ago
Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025 MINNEAPOLIS , May 12, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its latest spatial biology and cell and gene therapy workflow solutions at the American Society of Gene & Cell Therapy (ASGCT) 2025 meeting taking place in New Orleans between May 13 th – 17th at the New Orleans Ernest N. Morial Convention Center. prnewswire.com - 1 month ago
CMB.TECH announces Q1 2025 results on 21/05/25 Antwerp, May 12, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMBT”, “CMB.TECH” or “the Company”) will release its first quarter 2025 earnings prior to market opening on Thursday 21 May 2025 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter. globenewswire.com - 1 month ago
CMB.TECH CEO Speaks On Shifting Investor Focus From Asset Values To Sustainable Earnings Power Capital Link's Trending News Webinar Series featured this week a discussion with Mr. Alexander Saverys, CEO of CMB.TECH CMBT, who shared his views on the company's diversified business model, plans for decarbonization, and his vision for a maritime industry that balances tradition with bold innovation. benzinga.com - 1 month ago
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing Kytopen and Bio-Techne announce partnership on an integrated cellular engineering workflow to expedite cell therapy manufacturing. The TcBuster™ system offers a fast and scalable method to integrate large, multigene cargos with high editing efficiency in a single vector, while Flowfect® continuous flow technology enables the gentle, high-efficiency processing of billions of cells in minutes. prnewswire.com - 1 month ago
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference MINNEAPOLIS , May 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 10:40 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. prnewswire.com - 1 month ago
Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment in third-quarter fiscal 2025. zacks.com - 1 month ago
8. Profile Summary

Bio-Techne Corporation TECH

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 7.71 B
Dividend Yield 0.14%
Description Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Contact 614 McKinley Place N.E., Minneapolis, MN, 55413 https://www.bio-techne.com
IPO Date Feb. 9, 1989
Employees 3100
Officers Mr. Martin Wirtz Senior Vice President of Strategy & Corporate Development Mr. Kim Kelderman Chief Executive Officer, President & Director Ms. Cheryl Bethune Senior Vice President & Chief Human Resources Officer Mr. David Clair C.F.A. Vice President of Investor Relations & Corporate Development Dr. Matthew F. McManus M.D., MBA, Ph.D. President of Diagnostics & Genomics Mr. Gerry Andros Vice President of Sales and Marketing Mr. James T. Hippel CPA Executive Vice President of Finance & Chief Financial Officer Dr. Gary J. Latham Ph.D. Vice President & Chief Technology Officer Mr. Shane Bohnen Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer Mr. William A. Geist President of Protein Sciences Segment